Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 2/20 | 0.40 |
| ▸ | PDE4B known ✓ | Q07343 | 2/20 | 0.40 |
| ▸ | PDE4C known ✓ | Q08493 | 2/20 | 0.40 |
| ▸ | PDE4D known ✓ | Q08499 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3983498 | 0.90 | ALDH1A1 (0.51) | LMNAMAPK1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL3983514 | 0.90 | ALDH1A1 (0.51) | LMNAMAPK1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL3816675 | 0.88 | LMNA (0.55) | LMNAMAPK1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL5471995 | 0.87 | LMNA (0.42) | LMNAMAPK1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL4396358 | 0.86 | ALDH1A1 (0.48) | LMNAMAPK1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL3811662 | 0.84 | LMNA (0.52) | LMNAMAPK1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL27634843 | 0.82 | IDO1 (0.35) | LMNAMAPK1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL3812384 | 0.82 | ALDH1A1 (0.46) | LMNAMAPK1KDM4EALDH1A1HSD17B10 | |
| Formic Acid SCHEMBL4392627 | 0.81 | LMNA (0.49) | LMNAMAPK1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL4389747 | 0.81 | PDE4A (0.45) | LMNAMAPK1KDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569550-B2 | 14 and 15 membered ring compounds | GLAXO GROUP LIMITED (GB) | 2009-08-04 | — | — | US | disclosed |
| US-20070213283-A1 | Macrolides substituted at the 4\"-position | GLAXO GROUP LIMITED (GB) | 2007-09-13 | — | — | US | disclosed |
| US-20070185117-A1 | Novel 14 and 15 membrered ring compounds | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| EP-1628988-B1 | NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS | GLAXO GROUP LTD (GB) | 2006-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185117-A1 | Novel 14 and 15 membrered ring compounds | CYP51A1, LSS, IL17A | PDE4A 1612/4885PDE4B 1070/4885PDE4C 1276/4885 |
| US-20070213283-A1 | Macrolides substituted at the 4\"-position | IL4, CYP51A1, IL17A | PDE4A 789/4885PDE4B 810/4885PDE4C 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.